DNX Xenographting Report

17 July 1994

- DNX Corporation has reported that it has achieved a limited success in the transplantation of a pig's heart into a baboon. The company said that although the baboon died after only 19 hours, past attempts had lasted less than one hour. The extension in survival time was achieved through incorporation of human DNA into the pig, which helped in preventing hyperacute rejection normally associated with xenografting through the pacification of the host's immune response. The damage to the grafted tissue was milder than anticipated, said John Logan, chief scientist at DNX.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight